Focused On-demand Library for Aurora kinase A

Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.


The compounds are cherry-picked from the vast virtual chemical space of over 60B molecules. The synthesis and delivery of compounds is facilitated by Reaxense.


The library includes a list of the most promising modulators annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Also, each compound is presented with its optimal docking poses, affinity scores, and activity scores, providing a comprehensive overview.


We employ our advanced, specialised process to create targeted libraries for enzymes.


 

Fig. 1. The screening workflow of Receptor.AI

It includes comprehensive molecular simulations of the catalytic and allosteric binding pockets and the ensemble virtual screening accounting for their conformational mobility. In the case of designing modulators, the structural changes induced by reaction intermediates are taken into account to leverage activity and selectivity.


Several key aspects differentiate our library:


  • Receptor.AI compiles an all-encompassing dataset on the target protein, including historical experiments, literature data, known ligands, and structural insights, maximising the chances of prioritising the most pertinent compounds.

  • The platform employs state-of-the-art molecular simulations to identify potential binding sites, ensuring the focused library is primed for discovering allosteric inhibitors and binders of concealed pockets.

  • Over 50 customisable AI models, thoroughly evaluated in various drug discovery endeavours and research projects, make Receptor.AI both efficient and accurate. This technology is integral to the development of our focused libraries.

  • In addition to generating focused libraries, Receptor.AI offers a full range of services and solutions for every step of preclinical drug discovery, with a pricing model based on success, thereby reducing risk and promoting joint project success.

PARTNER
Receptor.AI
 
UPACC
O14965

UPID:
AURKA_HUMAN

ALTERNATIVE NAMES:
Aurora 2; Aurora/IPL1-related kinase 1; Breast tumor-amplified kinase; Ipl1- and aurora-related kinase 1; Serine/threonine-protein kinase 15; Serine/threonine-protein kinase 6; Serine/threonine-protein kinase Ayk1; Serine/threonine-protein kinase aurora-A

ALTERNATIVE UPACC:
O14965; E1P5F9; O60445; O75873; Q9BQD6; Q9UPG5

BACKGROUND:
Serine/threonine-protein kinase aurora-A, also known as Aurora kinase A, is essential for mitotic progression, regulating various stages from centrosome duplication to cytokinesis. It phosphorylates a wide array of substrates, influencing spindle assembly, chromosome alignment, and cell division. Additionally, it plays a role in microtubule dynamics and axon formation.

THERAPEUTIC SIGNIFICANCE:
The exploration of Aurora kinase A's functions presents a promising avenue for developing novel cancer therapies. By targeting the mechanisms of cell cycle regulation and mitotic progression, researchers aim to create treatments that can selectively inhibit the proliferation of tumor cells.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.


Page 8233 of 8789